BC Extra | Jan 30, 2019
Company News

Allergan sheds $4.5B in market cap on 4Q18 earnings

Allergan plc (NYSE:AGN) lost $13.57 to $145.12 on Tuesday after it reported a $4.3 billion net loss in 4Q18 and presented 1Q19 guidance well below the Street’s consensus. The stock move translates to a loss...
BC Innovations | Nov 6, 2018
Distillery Therapeutics

Infectious disease

INDICATION: Clostridium Cell culture studies suggest the tryptophan analogs 1-acetyl-β-carboline and turbomycin A could help treat Clostridium difficile infection (CDI). In C. difficile culture, the bacterial and fungal metabolite 1-acetyl-β-carboline and the antibiotic turbomycin A...
BC Innovations | Aug 16, 2017
Distillery Therapeutics


INDICATION: Stroke Rat studies suggest polymeric micelles loaded with a HMOX1 -encoding vector could help treat ischemic stroke. The polymeric micelles consisted of deoxycholic acid-conjugated polyethylenimine polymers loaded with a plasmid encoding HMOX1. In a...
BioCentury | Dec 31, 2016

Delivering takeouts

  BioCentury’s 25th annual Buyside View finds biotech investors focusing on mid-cap names with late-stage or marketed products that could become M&A targets. “The main theme playing at the moment is investors like us are...
BioCentury | Jan 11, 2016

Sowing season

Stephen Hansen, Associate Editor   BUYSIDE VIEW XXIV While the biotech sector's three-year rocket ride isn't likely to continue in 2016, fund managers are still anticipating a slew of high-profile milestones in the New Year....
BC Extra | Nov 5, 2015
Company News

Allergan strikes dry eye deal with Mimetogen

Allergan plc (NYSE:AGN) reported 3Q15 earnings and licensed dry eye candidate tavilermide ( MIM-D3 ) from Mimetogen Pharmaceuticals Inc. (Montreal, Quebec). Allergan did not give an update regarding merger talks with Pfizer Inc. (NYSE:PFE), which were disclosed...
BC Week In Review | Jul 13, 2015
Company News

Kythera sales and marketing update

Kythera launched Kybella deoxycholic acid in the U.S. to reduce submental (under chin) fat. The drug is a synthetic sodium deoxycholate . Kythera Biopharmaceuticals Inc. (NASDAQ:KYTH), Calabasas, Calif.   Business: Dermatology  ...
BioCentury | Jul 13, 2015

Mid-cap hot streak

Almost all of the biotech market cap tiers tracked by BioCentury ended the second quarter in the black. The lone exception was companies valued below $200 million, which collectively fell a median 1.2%. Big cap...
BC Week In Review | Jun 22, 2015
Company News

Kythera, Allergan deal

Allergan will acquire Kythera for about $2.1 billion in a cash and stock deal. Kythera shareholders will receive $60 per share in cash plus $15 per share in Allergan common shares. The $75 per share...
BC Extra | Jun 18, 2015
Company News

Allergan acquires Kythera for $2.1 billion

Allergan plc (NYSE:AGN) will acquire Kythera Biopharmaceuticals Inc. (NASDAQ:KYTH) for $75 per share, or about $2.1 billion in cash and stock. The price represents a 24% premium over Tuesday's closing price of $60.72. The deal...
Items per page:
1 - 10 of 28